-
-
-
-
-
-
-
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycl
-
-
-
-
-
-
-
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights
-
-
-
-
-
-
-
Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights
-
1,199,633 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

